AI cracked a 3-year lab mystery, Washington took the keys to GPT-5.6, and the AI trade blinked
Mon, Jun 29, 2026 · 10 stories
Derya Unutmaz, an immunologist, had been stuck on the same experiment for three years. This week he got unstuck, and the collaborator that broke the logjam was GPT-5. Not as a search box, as a thinking partner: it proposed the hypothesis his lab had missed. We have all heard the AI-for-science pitch on a loop. This is one of the first versions with a real name on it and a result on the other end.
Then the same technology spent the rest of the week making everyone anxious. OpenAI previewed GPT-5.6, codenamed Sol, and within days slowed the rollout at the White House's request, with Washington wanting a say in who gets access. The markets got jumpy too. Korean chip stocks fell 9 percent, SpaceX's brand-new bonds sold off days after drawing 89 billion dollars in orders, and the Bank for International Settlements warned an AI bust could leak from growth into credit. Micron posted a blowout forecast that bought the rally a day before it rolled over.
So that was the week. The clearest proof yet that these models can do real scientific work, landing in the same five days that the government decided it wanted a hand on the release lever and Wall Street started pricing in the downside. The capability keeps climbing. It is everyone's confidence around it that wobbled.
Top Stories
OpenAI
OpenAI detailed how immunologist Derya Unutmaz used GPT-5 as a reasoning partner to break open an experimental problem his lab had been stuck on for three years, generating the hypothesis that finally resolved it.
Why this matters:
The "AI for science" pitch has mostly been promise; this is a named researcher with a concrete, years-stuck result. The signal for builders and investors is not the model, it is the workflow: frontier models are starting to act as research collaborators on real open problems, not just literature search, and that is where durable scientific and commercial value will compound.
The Verge
OpenAI previewed GPT-5.6, codenamed Sol, then delayed and limited the rollout at the Trump administration's request, with the US government set to vet who gets access to the new flagship over safety concerns.
Why this matters:
This is a precedent, not a one-off. A private lab's flagship release is now gated by the state deciding who is allowed to use it, and stacked against Anthropic's ongoing export fight, model access is becoming a permissioned, regulated asset. Every startup built on the assumption that the best model is one API call away now carries political risk in its dependency stack.
Bloomberg
The AI trade had its first real two-way week: Korean chip stocks fell 9%, an "AI rout" exposed roughly $270 billion in speculative positioning, SpaceX's new $25 billion bonds sold off days after drawing $89 billion in orders, and the BIS warned an AI bust could spill from growth into credit.
Why this matters:
Micron's blowout forecast briefly revived the rally before it rolled over, and the speed of that reversal shows how crowded and leveraged the positioning has become. For anyone raising or deploying capital, AI infrastructure just stopped being a one-way bet, and the cost of being wrong now includes credit-market contagion, not just a drawdown.
Quick Hits
The Verge
OpenAI and Broadcom unveiled a custom LLM-inference chip, Big Tech's sharpest move yet to cut its dependence on Nvidia.
DeepMind
Google added computer-use (browser and UI control) to its cheap, fast Gemini 3.5 Flash model, pushing agentic automation down the cost curve.
MIT Technology Review
IBM detailed a sub-1nm 3D "nanostack" architecture it says could extend Moore's Law by another decade.
Financial Times
Apple lifted prices roughly 20%, blaming the AI-driven memory-chip shortage, the first time the buildout's cost has landed on consumer price tags.
Bloomberg
Qualcomm agreed to acquire the AI-infrastructure company Modular to push deeper into the data center.
Nature
An AI tool surfaced candidate compounds active against a hard-to-treat superbug, a concrete drug-discovery win.
TechCrunch
The Trump administration cleared Mythos 5 for use by more than 100 US companies and agencies even as Asian startups raced to ship Mythos-like models while the export ban drags on.
